𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection

✍ Scribed by Parke, Frank A. ;Reveille, John D.

Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
339 KB
Volume
51
Category
Article
ISSN
0004-3591

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Anti–tumor necrosis factor α therapy and
Anti–tumor necrosis factor α therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis
✍ Sebastian Schneeweiss; Soko Setoguchi; Michael E. Weinblatt; Jeffrey N. Katz; Je 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 126 KB 👁 1 views

## Abstract ## Objective To assess the association between the initiation of anti–tumor necrosis factor α (anti‐TNFα) therapy and the risk of serious bacterial infections in routine care. ## Methods This was a cohort study of patients with rheumatoid arthritis (RA) in whom specific disease‐modif

Comparison of drug retention rates and c
Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis
✍ Pan, Sophie Martin Du ;Dehler, Silvia ;Ciurea, Adrian ;Ziswiler, Hans-Rudolf ;Ga 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 108 KB 👁 1 views

## Abstract ## Objective Tumor necrosis factor (TNF) inhibitors have revolutionized the treatment of severe rheumatoid arthritis (RA), yet drug discontinuation is common. The aim of this study was to compare treatment retention rates and specific causes of anti‐TNF discontinuation in a population‐

Anti–tumor necrosis factor α therapy and
Anti–tumor necrosis factor α therapy and the risk of lymphoma in rheumatoid arthritis: No clear answer
✍ Deborah P. M. Symmons; Alan J. Silman 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 50 KB 👁 1 views

The authors are the principal investigators of the British Society of Rheumatology (BSR) Biologics Register. The BSR receives financial support for the Register from the manufacturers of biologic agents currently licensed for use in the treatment of patients with inflammatory rheumatic diseases. The

B cell depletion may be more effective t
B cell depletion may be more effective than switching to an alternative anti–tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti–tumor necrosis factor agents
✍ Axel Finckh; Adrian Ciurea; Laure Brulhart; Diego Kyburz; Burkhard Möller; Silvi 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB 👁 2 views

## Abstract ## Objective Patients with rheumatoid arthritis (RA) in whom the response to anti–tumor necrosis factor (anti‐TNF) therapy is inadequate have several therapeutic options, such as switching to an alternative anti‐TNF agent or initiating B cell–depleting therapy with rituximab (RTX). Alt